An official website of the United States government
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Trial Status: active
The purpose of this clinical trial (called the FLOTILLA study) is to give continued
access to the study medicines, as well as safety follow-up, for participants in prior
clinical trials of encorafenib and/or binimetinib.
All participants who took part in earlier encorafenib and/or binimetinib studies may
participate the FLOTILLA study if they are still benefiting from the use of the study
medicines. This will be determined by the study doctor. People may not participate in the
FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib.
Participants that had enrolled but had stopped receiving the study treatment in a prior
study cannot enrolled in this study. Participants in the FLOTILLA study will receive
encorafenib and/or binimetinib at the same dose and frequency as in their prior study,
for up to about 5 years.
Inclusion Criteria
Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade ≥3 or intolerable Grade 2 AEs considered to be related to study treatment.
Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.
Exclusion Criteria
Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
Additional locations may be listed on ClinicalTrials.gov for NCT05203172.
